A detailed history of Woodline Partners LP transactions in 89bio, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 172,779 shares of ETNB stock, worth $2.56 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
172,779
Previous 1,222,661 85.87%
Holding current value
$2.56 Million
Previous $12 Million 78.88%
% of portfolio
0.01%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$8.02 - $14.96 $8.42 Million - $15.7 Million
-1,049,882 Reduced 85.87%
172,779 $2.54 Million
Q2 2025

Aug 14, 2025

BUY
$4.83 - $10.57 $2.52 Million - $5.52 Million
521,907 Added 74.48%
1,222,661 $12 Million
Q1 2025

May 15, 2025

BUY
$6.18 - $11.66 $1.89 Million - $3.57 Million
305,928 Added 77.48%
700,754 $5.09 Million
Q4 2024

Feb 14, 2025

BUY
$7.03 - $10.05 $2.4 Million - $3.43 Million
341,479 Added 640.11%
394,826 $3.03 Million
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $392,633 - $515,332
53,347 New
53,347 $394,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $690M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.